$TGODF Building a Sustainable Business, From the Ground Up

November 4, 2019

• TGOD is defining industry standard in organic sustainability practices, follows a regenerative farming method
• Sustainability lends both ethical, business edge to companies, says TGOD leadership
• The company is dedicated to organic practices, sustainable principles

The only certified-organic scaled producer in the industry, The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is committed to more than just cultivating premium organic cannabis. TGOD works to cultivate a way of life, ensuring that from seed, soil and beyond, every step of the company’s cultivating process is designed to make a difference. As part of that commitment, TGOD is defining the industry standard in organic sustainability practices.

The Green Organic Dutchman follows a regenerative farming method, carefully considering the entire product life cycle in order to reduce the company’s carbon footprint in every way possible. Because of this deliberate approach, the TGOD organic cultivation process is exceptionally clean with a focus on the natural growth of the plan, ultimately resulting in the best cannabis Mother Nature can produce.

“Sustainability means my future and the future of our communities,” TGOD facilities engineer Richard Aranha stated in a news release (http://cnw.fm/8jQmw). “Our culture is designed around sustainable practices because sustainability gives an ethical edge to your company, but it also provides a business edge.”

With the future in mind, TGOD is dedicated to organic practices and sustainable principles, including the following:

• Recyclable packaging – The company packages its flower and oil products in recyclable glass; TGOD shipping containers use only recyclable paper;
• LED lighting – TGOD relies on LED lighting as the most efficient and impactful manmade light source to fuel growth of its plants;
• Hybrid facilities – The careful design of TGOD’s hybrid facilities allows for maximum absorption of natural sunlight. In addition, multiple filtration processes allow the company to recycle 90 percent of rainwater, which is then used to feed the plants;
• Energy efficiency – The company uses water-heat transfer, which provides heat for its hybrid facilities in the most energy-efficient, cost-effective manner; and
• Environmental advocacy. TGOD has partnered with several local groups, including Grand River Authority Conservation, to work on specific environmental priorities to ensure the land is protected and honored.

In addition to its commitment to sustainability, The Green Organic Dutchman prides itself on following a higher standard of organic growing, which includes creating a living soil rich in beneficial organisms with no synthetic chemicals used at any stage of cultivation. TGOD recognizes that growing certified organic cannabis is better for the community, the soil, the environment and – most importantly – the consumer.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://cnw.fm/TGODF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$OGI Petitioner Urges Iowa Cannabidiol Board to Add PTSD

November 4, 2019

For years, the residents of Iowa have lamented over the exclusion of PTSD from the state’s heavily restricted medical cannabis program. Medical cannabis is a potent natural medicine that can help manage a host of medical conditions. Luckily for people with PTSD, medical marijuana has been found to be effective at reducing the symptoms of the condition. Unluckily for the people suffering from this condition, the state’s medical cannabis program has, for years, failed to include it in its list of eligible conditions.

Iowans were disappointed back in 2014 when state lawmakers created its medical cannabidiol program but didn’t include PTSD. The condition was again excluded from the program when it was expanded in 2017, and last year, the Medical Cannabidiol Board rejected a petition to add PTSD to the list of approved conditions.

Interested parties have another chance to sway the decision. The Cannabidiol Board will, on Monday, review another petition by the residents of Iowa, urging the state to allow people living with PTSD to use medical cannabis as a treatment. Rebbeca Lucas of MedPharm wrote in the petition that “Americans had failed military veterans who have combat-related PTSD. We get to live how we live because they fight for us,” the petition says, “however, when our service members return, we, in essence, abandon them. We potentiate a stigma that it is strange for people, not just to be OK.”

Over the years, the effects of PTSD on military and law enforcement veterans have been studied. The country loses an average of 21 service members every day to suicide. Although 28 other states, including Minnesota and Illinois, allow PTSD patients to use medical cannabis, the state of Iowa still lags behind. One issue that has held back medical cannabis in this regard is the idea that people who do not have the condition will somehow outwit the system for a marijuana fix.

A testimonial that proved the invalidity of that train of thought was sent along with the petition. The author, whose personal details were redacted, was a former Iowa police officer who was relieved of his duty back in 2010 after being diagnosed with PTSD. The officer suffered from depression and suicidal thoughts for over a decade, was unable to find employment, and avoided using medical cannabis, saying that it had been so ingrained in him that marijuana was harmful. “Heck, I even put people in prison because they had or were selling marijuana.”

Eventually, the officer tried medical cannabis, and the PTSD symptoms reduced drastically soon after. “For the first time in 10 years, I felt normal again. I feel like I have my life back!”

Industry watchers believe that personal testimonies like that of the former law enforcement office are the reason that CBD companies like Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) and Willow Biosciences Inc. (CSE: WLLW) keep working so that many more people can have better lives despite the health conditions that they struggle with.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$LXRP Utah Farmers Report Successes and Challenges in First Hemp Season

November 4, 2019

Jud Haward is a hemp farmer from Utah whose crop is now drying in his barn after harvesting. He has used the hanging method to dry his plants and the drying hemp is filling the air with a heavenly cannabis aroma. He is proud of the hemp yields from his 10-acres despite having sold only a part of the crop.

Haward was among the first farmers in Utah to grow industrial hemp. Thus, he relied mainly on his instinct and little guidance from an expert to nurture his crop to maturity. The most nerve-wracking thing is, he was never sure if he was doing it right or wrong.

Utah has issued 220 industrial hemp licenses since the government legalized hemp production for industrial use.

A hemp license was regarded as a golden ticket because of the popularity of cannabidiol, also known as CBD oil, which is an extract of hemp. CBD oil can be used for medicinal purposes, and it can also be used in other products such as CBD deodorant or CBD hamburgers.

Since hemp crop comes with a promise of substantial financial gains, some farmers in Utah who are financially struggling have uprooted their hay and lettuce and replaced them with hemp. Others have mortgaged their farms for capital to invest in hemp.

Haward said that some farmers lost hope mid-way when their crop failed because of a lack of expertise, and it was hard to get information on hemp growth. The crop specialists were unreliable, and the some suppliers were unscrupulous.

Ruston Peterson owns a greenhouse where he grows hydroponic lettuce for commercial purposes. He sells his greens in Salt Lake City due to a lack of market in Utah, which is tiring and expensive. Earlier this year, Peterson was among those who decided to grow hemp in Utah.

However, growing the crop was more challenging than they thought, said Peterson. Some farmers, despite missing the growing window, still planted hemp, which led to crop failure. Others adhered to every rule about hemp farming, but nature took its course and some plants withered, while for some, the plants were invaded by frost.

The other challenge for the farmers was the state’s stipulation that hemp should have a THC concentration of 0.3% or less. This year, after testing the crop, the state destroyed 16,323 plants because their THC was above the 0.3% limit. This was a loss and a setback for the affected farmers.

According to the director of the hemp and medical marijuana program in Utah, Andrew Rigby, to achieve the 0.3% THC concentration, farmers have to choose the right seed and use the proper growing techniques.

The difficulties in distinguishing hemp and marijuana since they have similar structure and smell had the police confused. And thieves stealing the crop and passing it for marijuana to unsuspecting buyers caused additional problems for farmers.

Although Haward’s and Peterson’s first hemp crop was a success, the price of CBD oils seems to have dropped from $4,500 to $800 per liter. Now, their main focus is recouping their costs by finding the right buyers.

Hemp industry experts believe that companies like Marijuana Company of America Inc. (OTCQB: MCOA) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) hope that things will normalize as farmers gain more experience in growing hemp.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

$GNPX Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

$YGYI Completes BeneYOU, LLC Acquisition

$TGODF Committed to Producing Cannabis Officially Recognized as Organic

$OGI Stock Bounces Back From Low: What’s Lying Ahead?

Organigram stock has bounced back almost 20% from its 52-week low over the past few weeks. Let’s analyze whether Organigram Holdings (TSX:OGI) (NASDAQ:OGI) has reached the bottom or not.

There is absolutely no doubt that the marijuana industry has gone through a pretty tough period over the course of the past months, and many of the stocks have collapsed from their peaks this year. However, certain companies continue to do well despite a slowdown in the industry.

Regulatory and Supply Issues

If one is looking into marijuana stocks in November, then Organigram Holdings will likely jump out at them. The company is certainly at the pinnacle when compared against other marijuana companies of similar sizes. So let’s take a closer look at Organigram stock.

Like the majority of stocks in the marijuana industry, Organigram stock experienced steep declines, and since its listing on the NASDAQ earlier this year, it has lost as much as half of its value. Regulatory and supply issues were the main factors behind the decline. However, it is important to consider the factors that make Organigram Holdings a top stock pick for the month.

High Spending

The legalization of derivatives in Canada is a significant event, and the company is spending heavily in order to enter the market strongly. The spending may have affected Orgianigram’s stock price, but if the company can corner some portion of the market in Canada, then it could prove to be money well spent in the long run.

It’s also necessary to keep in mind that Organigram enjoys some key competitive advantages that could see the company growing rapidly in the long run. Organigram Holdings is based out of New Brunswick and remains the only marijuana company of its size that operates in the area. Its presence in that area makes it possible for the company to create a major stronghold in the eastern region. In addition to that, it has also acquired supply agreements in all 10 Canadian provinces.

Last but not least, one must also remember that the company’s production is based out of only one facility in Moncton. Other marijuana companies have been spending copious amounts of money in order to raise their production level in the meantime.

Analysts believe that Organigram could well turn out to be the first marijuana company from Canada to make a profit, and hence, Organigram stock is an attractive one to some.

$LXRP Proprietary Drug-Delivery System Featured in Peer-Reviewed Medical Journal

$YGYI First Marijuana Wedding Expo to Showcase How Marijuana Can Be Part of Your Big Day

October 31, 2019

Phillip Wolf developed the Cannabis Wedding Expo after noticing that there was little or no exposure for cannabis services. The expo was started in Colorado in the year 2015 after noticing that young entrepreneurs were interested in the hospitality and service side of marijuana, but they did not have a clue on the ways to market themselves.

The 12^th edition of Cannabis Wedding Expo will Debut in Toronto Canada this Sunday. It will be showcasing hemp gowns, bouquets made of buds, and flower vases that also serve as bongs.

The Cannabis Wedding Expo caters to couples who are looking for an alternative way to incorporate marijuana in their wedding in a tasteful manner. There will be 50 wedding experts, exceptional cannabis sellers, and bud-tenders.

According to Wolf, weed can be incorporated in other events, and they aim to show people different ways to do it. He further says that he intends to show people that apart from alcohol, weed can also be used at social events.

Wolf said, recently, there is a shift where people are seeking different options when they are out having fun. If someone does not want to have a drink, he or she can opt to smoke weed.

Clayton Armstrong is a bud-tender and co-owner of Bud Buffets says he aims to end the negative stigma linked with marijuana. Citing one of his company slogans, Armstrong said that we are past the days when people smoked weed in hiding.

Bud buffet works with events planners to make sure that they offer their clients luxury smoking and vaping accessories at their special events. The planners also make sure to moderate weed intake to the last gram.  However, the best thing for people is to bring your bud (BYOB), said Armstrong.

Jonathan Sora owns Higher Knowledge Company. The company conducts training sessions for wedding bud-tenders, teaching them how to pair a three-course meal with the three strains of marijuana. “Just like food is paired with wine,” said Sora. Sora said that the interest in his company has been soaring, and people have been very supportive.

It is a little over a year since Canada legalized marijuana; however, the means of distribution are still undefined.

Naz Neufeld, who is the co-founder of Thyme Studio, a floral design company, said that adding buds to bouquets could be termed as distribution when it’s just that, a bouquet.

According to Magnolia Pancorbo, her wedding guests are interested in the recreational nature of marijuana, so they are considering doing a weed wedding.

Wolf said that as laws regarding marijuana become more defined, people are going to incorporate weed into their events in different ways and the wedding expo is one way of showing them the possibilities of doing just that.

It would be interesting to get an honest opinion from longstanding marijuana companies like Youngevity International Inc. (NASDAQ: YGYI) and ChineseInvestors.com Inc. (OTCQB: CIIX) regarding whether they ever imagined that marijuana-themed weddings would be a reality at this point in time.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$TGODF U.S. Cannabinoid Market Including Hemp Now Projected to Reach $44.8 billion by 2024

October 31, 2019

Palm Beach, FL –October 31, 2019 – The U.S. and China are opponents in many categories today and years to come. In some of these interactions there are no winners or losers, however, the U.S. is the clear winner in the global hemp cultivation market. Hemp has more uses that most people would expect from fabric to medicinal uses, but it is the rise of the CBD market that makes this an important ‘win’. According to industry reports the U.S. and China are #1 and #2 respectively (by acreage). The country in 3rd place is not even half of China’s figures at #2. (Columbia). An article this month in Cannabis Business Times said: “The U.S. hemp-derived CBD market is expected to reach $23.7 billion by 2023, up from the current value of $5 billion, according to Brightfield Group. Thousands of farmers are ramping up production in response to the passage of the 2018 Farm Bill (which legalized hemp at the federal level), the expansion of state industrial hemp programs and the promise of profits.  Active cannabis companies in the markets this week include: Sugarmade, Inc. (OTCQB: SGMD), MariMed Inc. (OTCQX: MRMD), Marijuana Company of America, Inc. (OTCQB: MCOA), Kona Gold Solutions, Inc. (OTCPK: KGKG), The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF).

In the U.S., the profit potential of CBD is driving the growth in hemp cultivation, with about 87% of the 288,000 acres expected to be used for hemp-derived CBD processing in 2019. On a per-acre level, hemp for CBD could potentially generate $45,203 in revenue, compared with $773 for corn.” In yet another bout in the ring, the U.S. again comes out on top…: “… the total cannabinoid market in the U.S. — which includes hemp-derived CBD — will reach $44.8 billion by 2024.” So says an article in Green Entrepreneur reporting on: “Arcview Market Research and BDS Analytics…  seventh edition of their “State of Legal Cannabis Markets” report.

Sugarmade, Inc. (OTCQB: SGMD) BREAKING NEWS: Sugarmade, a major supplier to the hydroponic cultivation and hemp sectors, is excited to announce the closing of the Company’s acquisition of BZRTH, LLC (“BZRTH”), a leading ecommerce supplier to the rapidly expanding hydroponic agricultural space. The Company expects the new combined entity to drive EBITDA profitability, net-positive cash flows, and top-line sales of $37 million on a forward basis.

“As of today, Sugarmade is one of the largest publicly traded hydroponics companies in the world,” remarked Jimmy Chan, CEO of Sugarmade. “The most important idea we want to convey to our committed shareholders right now is that this move was not a one-off deal. It’s part of a multi-step roll-up strategy designed to create the dominant force in this market as we look ahead to a world where hydroponics becomes the difference between success and failure for producers in the rapidly growing market for hemp and hemp-related crops in North America.”

Management notes that the integration of BZRTH implies the vertical integration of ecommerce through ZenHydro.com (and several additional hydroponics ecommerce sales portals) with a 55k sq. ft. fulfillment center and a market leading logistics platform. The Company also continues to negotiate with several other entities to continue to drive its aggressive M&A-based expansion strategy.

Mr. Chan continued, “We plan to continue to be very aggressive on the M&A side. This space is extremely ripe for disruption through consolidation of successful entities. And we have strong momentum right now to snowball this process by combining and coordinating undervalued assets into a single dominant market force that benefits from powerful overlapping growth in ecommerce, hemp, and hydroponics.”   Read this and more news for Sugarmade at:  https://www.financialnewsmedia.com/news-sgmd/

Other recent developments in the cannabis/cbd/hemp industries:

MariMed Inc. (OTCQX: MRMD) a premier cannabis and hemp multi-state operator focused on health and wellness, has signed a definitive agreement to license its market leading brands and products, Betty’s Eddies™ and  Kalm Fusion™ to Tropizen of Puerto Rico. Additionally, MariMed will become a licensee to manufacture and distribute Tropizen’s unique tropical products, Pique hot sauce and Real Fruit Gummies in the six states that MariMed serves in the US. The companies are in final review of production requirements to set launch dates for each product by territory.

Tropizen is a leading cultivator, manufacturer, distributor and retailer of cannabis products in Puerto Rico servicing nearly all of the island’s 100 dispensaries with world-class flower, edibles, topicals and concentrate products. Puerto Rico’s medical market is experiencing dynamic growth. The latest data from the territory’s government show that the number of registered medical patients in July exceeded 92,000 or 3% of the island’s population. According to MJBiz Daily, over 15,000 new patients registered between May and July of this year.

Marijuana Company of America, Inc. (OTCQB: MCOA) and MCOA’s wholly owned subsidiary, hempSmart, Inc., jointly announced a hemp extract and CBD product supply agreement where hempSmart will market MCTC’s powdered drink mixes and other CBD edibles online and via hempSMART’s thousands of network marketing partners. The products, branded under the trademarks: Hemp You Can Feel™ and Gummies You Can Feel™, to be supplied by MCTC and will be based on the MCTC’s patent pending cannabinoid infusion technologies that offer super high bioavailability of cannabinoids.

“There are now hundreds of CBD brands in the marketplace, so differentiation is critical,” commented MCTC CEO, Arman Tabatabaei. “Our differentiation is strong by way of our unique super bioavailability infusion of broad spectrum hemp extracts and cannabinoids. We are very excited to be working with Marijuana Company of America and hempSmart as our first customers for our unique hemp extract powdered beverage and edibles products.”

Kona Gold Solutions, Inc. (OTCPK: KGKG) a hemp and CBD lifestyle brand focused on product development in the functional beverage sector, recently announced it has signed a distribution agreement with Ohio based Beverage Distributors Inc.  Beverage Distributors brings Kona Gold Hemp Energy Drinks and HighDrate CBD Energy Waters into the state of Ohio.  Beverage Distributors will distribute the Company’s popular products across the entire state of Ohio, covering key markets.

Beverage Distributors Inc., is an Ohio corporation started in Cleveland Ohio in 1933.  Owned then by Frank Blazy and then by his son, Henry, the Company operated successfully benefiting from quality products, good service, and a reputation for both.  The same still stands today, 86 years later.  Beverage Distributors is owned and operated by the Conway Family.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD.TO) (OTCQX: TGODF), a leading producer of premium certified organic cannabis, recently unveiled a new strategic plan, including a series of actions to reduce the Company’s financing requirements while maintaining its path to profitability.  These actions will result in increased agility, lower capital requirements and an optimal production capacity to serve the organic segment.

“These actions are logical next steps in TGOD’s road to profitability.  While we are committed to – and our strategy continues to leverage – our unparalleled scale as an organic producer as well as our international assets, we have identified areas where our scale would not provide for meaningful returns in the near term given the slower pace of legal market conversion.  We will optimize our operating efficiency by deferring excess capacity and expenses, whether they center on production facilities, international expansion projects or technology,” commented Brian Athaide , CEO of TGOD.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated ninety five hundred dollars for news coverage of the current press releases issued by Sugarmade, Inc. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$SRAX Ahead of Curve in New California Compliancy Law

$POAI Milestone in Building AI-driven Predictive Models of Ovarian Cancer

Helomics subsidiary begins sequencing retrospective ovarian cancer cases from UPMC-Magee collaboration, advancing POAI’s CancerQuest 2020 initiative

MINNEAPOLIS, Oct. 31, 2019  — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that its Helomics subsidiary has begun to sequence tumor cases from its UPMC Magee collaboration (http://nnw.fm/4uKXL).

Helomics’ partnership with the UPMC Magee Women’s Hospital focuses on analyzing the genomic and drug response profiles of women with ovarian cancer to build AI-driven predictive models’ terms of therapy response. This collaboration is a key benchmark in Predictive Oncology’s Cancer Quest 2020 project as it takes a retrospective look at around 400 ovarian cancer cases that were profiled for drug response by Helomics, for which UMPC Magee has outcome data.

“These retrospective ovarian cancer cases were profiled Helomics as early as 2010; hence, we have 10 years’ worth of drug treatment data, survival and other outcome measures we are gathering from Magee’s clinical databases,” stated Helomics CTO Dr. Mark Collins. “We are now sequencing these cases, looking at both the tumor mutations (genome) as well as tumor gene expression (transcriptome) to build a comprehensive multi-omic picture of the tumor. We are also using deep learning on histopathology images of the tumor tissue (tissue-omics) to add an additional dimension to this multi-omic profile. We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome (prognosis).”

This first AI-driven predictive model will be highly valuable in partnerships with pharma companies to drive the discovery of new targeted therapies for ovarian cancer. Once clinically validated, Predictive Oncology expects it will use this predictive model for clinical decision support, helping guide oncologists to better target therapies based on the patient’s tumor profile.

About Predictive Oncology

Predictive Oncology (NASDAQ: POAI) is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The Company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow.

Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, 38,000+ specific to ovarian cancer. The Company’s data is highly differentiated, having both drug response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development.

For more information, visit the Company’s website at www.predictive-oncology.com.

Contact:
Gerald Vardzel Jr.
Helomics Corporation, President
A division of Predictive Oncology Inc.
91 43rd Street, Suite 110
Pittsburgh, Pennsylvania 15201
412.432.1508
GVardzel@Helomics.com

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Forward-Looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; and the market price of the Company’s common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive Oncology’s ability to implement its long range business plan for various applications of its technology; Predictive Oncology’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive Oncology’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive Oncology’s financial position. See Predictive Oncology’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.

$LXRP Stock Jumps After FDA Announcement on Smokeless Tobacco Products

October 31, 2019

• LXRP stock jumped by 24 percent following the FDA’s announcement
• FDA recently granted the first-ever, modified-risk orders to eight smokeless tobacco products
• DehydraTECH technology enhances oral delivery of nicotine

The recent climb in the stock price of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) looks to be the harbinger of a bright future for the innovative global developer of drug-delivery platforms. After the FDA announced it had authorized the marketing of products through the modified-risk, tobacco-product (MRTP) pathway, LXRP stock jumped 24 percent, up to $0.72 from $0.58 on the OTC Markets. The rapid rise in Lexaria stock price is a sure indication that investors are betting some of those product categories approved by the FDA could benefit from Lexaria’s drug-delivery platform. The company’s patented DehydraTECH(TM) technology has been shown to enhance the oral delivery of nicotine and a wide range of other active pharmaceutical agents.

The FDA announcement is a victory of vindication for companies such as Lexaria that are developing smokeless nicotine products and technology. While smokeless tobacco products are widely sold, in the past they cannot profess to be healthier than cigarettes to use. However, following the FDA announcement, some can. On October 22, 2019, the FDA allowed (http://cnw.fm/PaC87) eight smokeless-tobacco products to make the claim that their use “instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

The FDA approval of the “modified risk” claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are addictive and may, according to some studies, induce the onset of cardiovascular, respiratory and gastrointestinal disorders.

The patented DehydraTECH drug-delivery platform mitigates a serious limitation to nicotine ingestion. The human GI system struggles to process nicotine in the forms in which it is presently offered, one reason why there are currently no edible, nicotine, manufactured products available, although some natural foods – eggplant, green pepper, potato, tomato – do contain nicotine. However, DehydraTECH employs a delivery mechanism that improves the bioabsorption and bioavailability of many ingestible substances, as well as their taste and smell, by using lipophilic agents. Application of the technology extends beyond nicotine to non-psychoactive cannabinoids, vitamins and non-steroidal anti-inflammatory drugs (NSAIDs).

Lexaria has licensed the DehydraTECH technology to a number of companies, including one of the world’s largest tobacco corporations, in a collaboration to pursue the development of reduced-risk, oral-nicotine consumer products. Lexaria recently provided an update on that partnership. “Most of the investigation and work within this first phase of the project is either complete or significantly underway, with one remaining aspect ready to commence imminently,” the company reported (http://cnw.fm/9cmnP). “To date, results have been positive and are supportive of successfully completing this first phase. Successful completion of phase one will be the first step in developing commercially viable products using Lexaria’s technology.”

As of July 2019, Lexaria had nine corporate licensees, with whom it had signed 11 licensing agreements to develop products using its DehydraTECH absorption technology (http://cnw.fm/cO9bK). These are potentially lucrative six-figure contracts that typically yield 90 percent plus of revenues as profit. Tobacco continues to be an area of opportunity. Presently, the tobacco industry generates about 20 times more revenue than the cannabis industry

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$GGBXF Parents of Epileptic Teen Plead For Easier Access to CBD Prescriptions

October 31, 2019

Young Bailey Rankmore suffers from Lennox-Gastaut syndrome, a particularly nasty form of epilepsy that sees him having up to 100 seizures on a daily basis. He is the latest in an increasing number of people in the UK who have used CBD to help manage severe conditions.

His parents, Craig and Rachel Rankmore, have pleaded with the NHS (National Health Service) to make it easier to access prescriptions for medical cannabis. After running out of conventional treatments for their son, they decided to think outside the box, settling on a private CBD prescription when he was fourteen. “He’d have a minimum of 100 big seizures a day,” they said, “the ones people associate with shaking on the floor. We’d seen him in bed, lying there completely lifeless, and we both agreed we’ve got nothing to lose.”

In the episode of Countryfile Diaries, in which they talked about Bailey’s condition, they said that after switching to CBD treatments, they noticed a big difference. Bailey was calmer, and the frequency of his seizures reduced so much that he could now take part in activities that would have been impossible before.

Although a change in the law last year made medical cannabis legal in the UK, doctors have been reluctant to prescribe CBD medication. The claims of cannabidiol’s efficiency are backed by a ton of anecdotal evidence, but little scientific research on the efficacy, safety, and side effects has been carried out. Due to this, most doctors are slow to believe the claims.

This has left the Rankmores in a precarious position. Since they don’t have an NHS prescription, they import medicine from the Netherlands at a high cost. “The bottle of CBD oil you get in Holland is £182 ($234.7). By the time that bottle of oil comes to our pharmacy,” they said,” that bottle of oil becomes £500 ($644.75), and he goes through three bottles of oil a week.”

The Rankmores were among a group of UK parents of children with severe epilepsy who were left in a bind after the body that recommends NHS spending declined to back medical cannabis treatment for children on the health service. According to the National Institute for Health and Care Excellence, there had not been enough evidence at the time to prove that CBD helped patients. The institute called for further research.

A spokesman from the Cardiff and Vale University Health Board said it had been in contact with the Rankmores, adding that they would continue to work with them to best manage his condition in the future.

The Department of Health and Social Care said that “the government is working with the health system, the industry, researchers and others to improve the evidence base for these products so that decisions can be made about public funding, and to provide clinicians with further support and guidance on prescribing these products where clinically appropriate.”

It is unfortunate that patients like Bailey Rankmore have to suffer needlessly when CBD can ease their condition. Experts believe CBD companies like VPR Brands LP (OTCQB: VPRB) and Green Growth Brands Inc. (CSE: GGB) (OTCQB:GGBXF) must be extremely frustrated each time a story like that of the Rankmores comes to light when there is an abundant supply for CBD to help severely ill kids.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$TGODF How Investors Can Capitalize on Europe’s Booming CBD Market

While Canada may be leading the field in terms of fully legal cannabis, Europe’s CBD market is quietly setting out its stall for a huge future. Analysts at the Brightfield Group predict the CBD market across the Atlantic to soar from $318 million USD in 2018 to $416 million USD this year, and even further to $1.7 billion USD by 2023. With the Canadian market is capturing most of the headlines right now, it could be easy for growth of that scale to go under the radar of most investors. Thankfully, we’re here to put in the groundwork, so you don’t have to.

Legal Status of CBD in Europe

Thanks to somewhat of a loophole in European Union regulations, most CBD products are classified as Novel Foods, which is open to interpretation by each of the 27 member states. In some of the EU’s largest countries, like Germany and the UK, CBD products can be found on the shelves of nearly every pharmacy, supermarket, or health store.

Other countries are a little stricter, like Austria, where regulators have completely banned the sale of CBD products, or, in Ireland’s case, issued warnings to retailers about stocking such products but stopped short of a complete ban amid a lobbying campaign to fully legalize medicinal cannabis.

So that status of CBD in Europe is a little hazy from state to state, but an application from Czech firm Cannabis Pharma could provide greater clarity. It submitted an application for a CBD-based food supplement product to the European Food Safety Authority earlier this year, and a spokesperson for the regulatory body said the European Commission is presiding over the case before passing it on to regulators. If that application is successful, CBD will be added to the list of permitted food/ingredients, and so, conditions of use will be specified.

Until that ruling is passed, however, companies continue to thrive in the regulatory grey area.

What are the Big CBD Stocks in Europe?

With companies based in Europe hesitant to go public due to the uncertain legal status of CBD and cannabis in the EU, North American companies have seen the opportunity to get ahead of the game without fear of regulatory repercussions. Let’s take a look at some companies asserting an early lead:

GW Pharmaceuticals (NASDAQ:GWPH) is actually headquartered in Cambridge, England, but lists on the NASDAQ. The company manufactures a CBD drug called Epidiolex, which has already been prescribed to more than 12,000 patients and seen really positive phase-three trial results for treatment of childhood epilepsy. This has led GW Pharma to post net sales of $68.4 million USD during the most recent quarter and $101.9 million USD over the first half of 2019. GWPH stock will set you back a pretty penny, however, currently trading at $134.06.

StillCanna Inc (CSE:STIL) (OTCPK:SCNNF) is a Canadian company that has been making some very promising moves into the European CBD market. In May, the company acquired Polish hemp company Olimax, a licensed cultivator, extractor, and formulator of CBD. This purchase makes StillCanna, by far, the largest hemp cultivator in Poland and, when combined with its Romanian facilities, one of the largest in the continent.

Most notably to investors is StillCanna’s patented hemp production process, which maximizes CBD content and allows for two crop yields per year. By the end of this year, StillCanna will be able to produce up to 16 million grams of CBD and plans on doubling that output in 2020. By 2021, the company expects to be cultivating 12,500 acres and produce up to 60 million grams, with still plenty of room to grow beyond that. StillCanna is so serious about its European operations that its CEO relocated across the Atlantic in July.

The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF) entered the European CBD market via a joint venture with Knud Jepsen, which received cannabis business authorization from the Danish Medicines Agency. Then, in May, TGOD entered the German CBD market through its subsidiary, HemPoland, paving the way for its premium CBD brand to soon hit the shelves of German pharmacies. TGOD stock has been struggling in its home market amid financing concerns, and so the potential in Europe could provide a light at the end of the tunnel.

The Takeaway

CBD markets have exploded around the world thanks to its supposed miracle medicinal properties. While a lot of those claims remain mostly unproven, there is no doubting that demand is only going to increase. To capitalize on that demand, winning the minds of the investment community will be essential in Europe, and the only way to really achieve that is to get investing.

$POAI Valuable Database Offers Hope to Cancer Patients of Today and Tomorrow

October 30, 2019

$OGI Illinois Hemp Farmer Shares Experience of Going Back to Farming Basics

October 30, 2019

It is the middle of the hemp harvest season, and farmers from Warren County, among them Andy Huston, the founder of American Hemp Research, are just beginning the harvesting process. He is one of the first farmers to grow hemp legally in Illinois and he shared what the journey has been like.

Huston said that farmers in Warren County are harvesting hemp manually, and it is hard work; he says it seems they have gone back several decades.

The Industrial Hemp Act, which legalized the growth of hemp in Illinois, was signed back in August 2018 by the former Illinois Governor, Bruce Rauner. When the Farm Bill which legalized industrial hemp production was passed in December 2018 by Congress, Illinois can now export the extracted CBD oil to other states.

Huston said the act of harvesting hemp is all new and that they are figuring things out as time goes by.

He added that hemp could not be harvested using modern farming equipment because when he tried using the combine harvester, most of the crop was left behind on the field. He further said that since hemp is relatively new, there are no specific tools for harvesting the plant.

Huston hopes that come next year; harvesting methods will have improved. However, the current model of harvesting has provided an avenue of learning for him and his team. Last year he harvested his hemp with the help of a research grant. This year, Huston has more than 90,000 seeds.

Logan Bird, another American Hemp Research farmer, said that hemp farmers are using different techniques and different pieces of machinery when harvesting their plants.

Bird says that harvesting by hand is a lot of hard work and that it slows down the harvesting process. And, he estimates harvesting to take another two weeks.

Andy Huston planted five different strains of hemp using different farming techniques. His hemp crop is going to be used for CBD oil extraction.

The weather is also a massive contributor to harvesting delays in Illinois. Prevention of mold formation during the bagging process requires hemp to be dry during harvesting. Since there is much moisture in the atmosphere in the morning, Huston and his team preferred to harvest the crop in the afternoon when the air was less dense.

According to Huston, the harvested hemp is good and dry and appealing to the eyes because there is no mold or dust present. He believes that the manual method of harvesting hemp to be working out well.

Huston is a 6^th generation farmer, and this year he also cultivated corn and soybeans. He adds that as a hemp farmer one will have to do more weeding, walking around the farm, and paying attention to every detail about the crop.

He also says that from the day he planted the crop, not a day has passed on which he has not gone out to the field. He further noted that the new hemp strains are perfect for the Illinois climate, and irrigation is not necessary because there is moisture in the air.

Compared to the western states, Huston is positive that Illinois farmers will have an easy time in terms of cost when producing hemp.

Analysts believe that hemp companies, such as Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI), are glad that despite the challenges faced, hemp farmers are hopeful things will be better in the coming seasons.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

$GWPD Launches Proprietary, Cost-Effective Growth Medium

$POAI Delivering Precision Medicine’s True Potential

$OGI Expelled Student Using Medical Marijuana Sues College for Discrimination

October 29, 2019

In America today, the conflict between federal and state marijuana laws has turned colleges into a battleground as students who are on medical marijuana come together to challenge campus policies that were formed in a different era.

Students disciplined for using medical marijuana in legal states are filing lawsuits against their schools. College officials argue that if the colleges fail to adhere to the federal law that terms marijuana as an illegal drug that is not accepted for medical use, their college could lose federal funding.

Sheida Assar has polycystic ovary syndrome whose symptom is chronic pain. She uses medical marijuana to manage her pain. Last month, she was expelled from Gateway Community College in Phoenix after testing positive for marijuana, which violated the school’s drug policy, said Assar.

According to Assar, an instructor told her that as long as she presented her medical marijuana card, she would have no problems. She further said that she was studying diagnostic medical sonography and never attended class under the influence and that she uses medical marijuana to help with insomnia.

The 31-year-old Assar said that she was yanked out of class like a criminal in the middle of school and escorted to administration. She further said that under the Arizona medical marijuana law, the act was outright discrimination and violation of her rights.

Nursing students and other medical specialties who must undergo compulsory drug testing as per the school policies are the ones raising the legal challenges.

The college employees who serve the students with their health-related needs are the ones who issued Assar and other students with the right to use medical marijuana, only for the higher ranking officials to issue disciplinary action later on.

Assar said that she is suing Gateway for the money spent on tuition, which was $2000 and other educational expenses. She also intends to seek more money in damages. She further said that her lawyer contacted the school.

A 2012 state law that termed it illegal and criminal to possess or consume marijuana in college campuses was overturned last year in a ruling by the Arizona Supreme Court.

Christine Lambrakis, the Gateway spokeswoman, said that she could not comment on Assar’s status at the school and that the college is still prohibiting the use of marijuana. She further noted that although the policies will not change in the meantime, the school is working on reviewing them.

Experts expect the entire marijuana industry, including Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) and Dama Financial to follow these cases brought against colleges since the outcome is likely to prompt states to compel higher education institutions to bring their policies into alignment with the current medical marijuana laws.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$GGBXF CBD is Quickly Becoming the Most Searched Topic on Google

October 29, 2019

Palm Beach, FL – October 29, 2019 — CBD is quickly becoming one of the most widely searched terms on Google, leading many to believe the cannabis boom is just getting underway.  In fact, “CBD has become insanely popular,” said Dr. John W. Ayers, vice chief of innovation at the University of California, San Diego’s Division of Infectious Disease and Global Public Health, as quoted by MarketWatch. “Three years ago, there was essentially no one searching about CBD online, but now there are an estimated 6.4 million unique searches each month.” That’s leading to a wide range of opportunity for companies including Veritas Farms Inc. (OTCQB:VFRM), Green Growth Brands Inc.(CSE:GGB)(OTCQB:GGBXF), Curaleaf Holdings Inc. (CSE:CURA) (OTCQX:CURLF), Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB), and Cronos Group Inc. (NASDAQ:CRON).

Veritas Farms Inc. (OTCQB:VFRM) BREAKING NEWS: Veritas Farms Inc. just announced that the company is sponsoring the 2019 Malibu Marathon.  As a part of the sponsorship, The Company will be included in all media and promotional campaigns and will have a large booth and multiple activations at both The Malibu Health & Fitness Expo on Saturday, November 2^nd and at The Malibu Half Marathon and Beach Festival on Sunday, November 3^rd at Zuma Beach in Malibu, California.  The Company’s tented booth is located near the finish line at the entrance to the festival. From this location, the Company will be sampling its complete line of full spectrum hemp oil products and incorporating them into various activations.  Throughout the weekend, runners, their guests and other event attendees will be able to participate in and enjoy free full spectrum hemp oil massages, guided meditations, CBD Yin Yoga sessions, Acro-Yoga demonstrations and educational discussions on full spectrum hemp oil and the hemp industry. Derek Thomas, Vice President of Business Development, commented “We are excited to sponsor the Malibu Marathon. California is a major market for Veritas Farms, and this is a effective opportunity to engage with, educate and sample one of our core target demographics.”

Other cannabis-related developments from around the markets include:

Green Growth Brands Inc. (CSE:GGB)(OTCQB:GGBXF) just announced that it has opened its 150^th Seventh Sense Botanical Therapy CBD mall-based shop. The first Seventh Sense shop opened in early February. GGB will provide a sales update on the performance of Seventh Sense® shops and eCommerce on its earnings call for fourth quarter and fiscal year 2019 ended June 30. The call will occur on Thursday, October 24th, 2019.  In the interim, the Company would like to share a progress update on the expansion of Seventh Sense.

Curaleaf Holdings Inc. (CSE:CURA)(OTCQX:CURLF) announced that on Friday, September 27, 2019 Executive Chairman Boris Jordan purchased 100,000 shares of Curaleaf stock on the open market at an average price of $8.21 per share.   Executive Chairman Boris Jordan commented, “This is an exciting time for Curaleaf and our industry, and I have never been more confident in our future. Curaleaf is well positioned for long-term growth and profitability. Our industry is on the brink of tremendous growth, especially as lawmakers on both sides of the aisle are recognizing the need to advance regulation like the SAFE Banking Act. Curaleaf is in the best position to lead this industry and create value for shareholders for the long-term.”

Aurora Cannabis Inc. (NYSE:ACB)(TSX:ACB) announced plans for the roll-out of vapes, concentrates, and edibles when they are permitted for sale to consumers in December. The Company has prioritized its resources to prepare for a successful initial launch that will support an ongoing replenishment strategy to help ensure consumers across Canada will have access to a diverse portfolio of high-quality derivative products they want to buy.  “Aurora’s Product Development and Insights teams have done tremendous work to formulate new products in a variety of formats that we think will exceed consumer expectations and drive category growth,” said Aurora CEO Terry Booth. “Aurora has built industry-leading cannabis capacity and scalability supported by our consumer research and retail distribution bench strength to launch this next generation of cannabis products into the Canadian market. We are ready to ship product as soon as the regulations allow and are excited for consumers and patients to finally have access to a greater selection of product forms. We are already working on expanding the range of new products beyond those that will initially launch.”

Cronos Group Inc. (NASDAQ:CRON) noted the separately announced closing of the AUD$20 million initial public offering of Cronos Australia Limited.  Under the offering, Cronos Australia issued 40 million new shares at an offering price of AUD$0.50 per share (the “Cronos Australia IPO”). Cronos Australia expects to start trading on the Australian Securities Exchange on a deferred settlement basis on November 7, 2019.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM was compensated thirty five hundred dollars for news coverage of current press releases issued by Veritas Farms Inc., by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

$GWPD Launches “Prolific” Nutrient Line that Maximizes Plant’s Genetic Potential

Proprietary, cost-effective growth medium produces clean herbs and vegetables

CORONA, Calif., Oct. 29, 2019  — GP Solutions, Inc. (OTC:GWPD), the developer of “GrowPods” – proprietary, automated micro-farms, debuts Prolific – a unique, proprietary soilless growth medium and nutrient line that is free of human and sewage waste. Prolific was formulated by GP Solutions’ in-house scientists, and is comprised of organic ingredients.

“Our objective was to develop a growth medium that will help give plants the proper nutrients they need to reach their genetic potential,” said George Natzic, President of GP Solutions. “Through our research and development, we created an ideal composition of natural ingredients that provide rich, contaminant-free growing conditions.”

Natzic continued, “GP Solutions’ Prolific is an excellent choice for growing organic vegetables and herbs in enclosed growing environments, such as indoor farms of any size, greenhouses, potted plants, and shipping container farms. Prolific provides an all-in-one solution that is suitable for beginners, advanced gardeners, and professional farmers.”

Prolific requires little fertilization to maintain plant vigor. The growth medium can be reused time and time again, making Prolific cost-effective and sustainable, while helping to promote a zero waste environment.

Prolific contains a microbiological diversity of beneficial fungi and bacteria that help keep the growth medium free of harmful pathogens. These all-natural ingredients also help eliminate burning (a common problem with most fertilizers), and is free of pesticides.

Prolfic comes pre-packaged for the convenience and ease-of-use.

Prolific will be available in better garden centers, farm equipment and materials stores, and online at the GP Solutions’ website.

For information on Prolific or on GrowPod automated micro-farms, visit: www.growpodsolutions.com, or call (855) 247-8054.

Forward-Looking Statements
This release includes predictions or information that might be considered “forward-looking” within securities laws. These statements represent Company’s current judgments but are subject to uncertainties that could cause actual results to differ. Readers are cautioned to not place undue reliance on these statements, which reflect management’s opinions only as of the date of this release. Company is not obligated to revise statements in light of new information.

Connect:

Email: info@growpodsolutions.com

Website: www.growpodsolutions.com

Facebook: facebook.com/GrowPodTechnology

Twitter: @GrowPodSolution

For Media Contact: Hello@inov8.us

$POAI Achieves Financial Milestone via Largest Single-Hospital STREAMWAY(R) System Sale

$LXRP Why You Will Not Get Addicted to CBD

October 28, 2019

Will I get addicted to CBD? That’s the million-dollar question. It is, after all, closely related to the infamous drug marijuana. The cannabis extract is all the rage now, and plenty of people are using it through edibles, CBD pens, medicines, and oils. It is therefore not surprising that many are wondering whether CBD is addictive.

It’s a legitimate question, especially considering the immense demand the products have garnered, coupled with how easily accessible it is. It is only last year that the Farm Bill legalized cultivating industrial hemp, the plant that produces cannabidiol (CBD). Given cannabidiol’s relation to its infamous psychoactive cousin, THC (tetrahydrocannabinol), a cannabinoid wrapped in controversy, it would be natural to pose such a question.

Well, the World Health Organization (WHO) answered this question in a report which examined a ton of things about CBD, including the wonder drug’s potential for abuse. The report said that a “single-dose administration of cannabidiol had been valued healthy in volunteers using a variety of tests of abuse potential as well as physiological effects in a randomized, double-blind placebo-controlled test.”

The report further stated that an orally administered dose of 600mg of CBD did not differ from placebo on the scales of the Addiction Research Inventory, a 16 item Visual Analogue Mood Scale, a subjective level of intoxication, or psychotic symptoms.

A second inspection was conducted, and the report published by WHO says that “the results of this analysis demonstrated that CBD was placebo-like on all measures (including visual analog scales, psychomotor performance such as the digit symbol substitution task, heart rate, and blood pressure).

This is good news for CBD users, especially those that use it to manage medical conditions. Over the years, users have claimed that cannabis products have given them relief from ailments such as chronic pain, insomnia, anxiety, and depression. The FDA even approved a CBD-based drug to treat seizures caused by epilepsy in children. Apart from people with severe issues, there are lots of people using CBD for a variety of other reasons.

The fact that cannabidiol passed abuse potential tests and was found to have no negative attributes is a godsend to such people. They’ll be able to use the CBD products to manage their ailments and get a better quality of life without worrying about getting addicted to their medication.

The debate on the habit-inducing capabilities of cannabis in general still rages on, but CBD uses can rest easy knowing they are safe.

Industry analysts believe that CBD companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and SinglePoint Inc. (OTCQB: SING) have always had a clean conscience due to their belief that CBD isn’t addictive and is safe for all to use.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$CNPOF $RIV.V Stock Gains on Receipt of New License and Strategic Partnership

RIV stock is in the green on Friday after Canopy Rivers (TSX:RIV) (OTCPK:CNPOF) announced that it had received approval from Health Canada to begin selling cannabis oil products, as well as unveiling a new partnership with cannabis brokerage and services company Kindred Partners.

Expanded License Approval for Radicle

The new license from Health Canada has been awarded to Canopy Rivers’ wholly-owned subsidiary Radicle Medical Marijuana and will allow the company’s medical patients broader access to other products in its craft cannabis selection. The company currently owns a 24% stake in Radicle, having invested $10 million CAD earlier this year.

As part of the investment, Canopy Rivers receives a long-term royalty cash flow stream with a minimum annual payment of $900,000 CAD over a 20-year term. RIV stock is currently trading up 5% following the announcement.

RIV Stock Looks Towards 2.0 Market

Supply and distribution issues have wreaked havoc on pot companies in the first year of legalization. With RIV stock dropping 75% in the first year of legalization, Canopy Rivers has looked ahead to the 2.0 market to address these issues. The partnership will see Kindred Partners, which is a subsidiary of Breakthru Beverage Group, provide its expertise in working with Canadian regulators, licensed producers, and retailers to broker regulated cannabis products for the adult-use market.

After sinking to a year-low earlier this week, RIV stock is recovering slightly following this deal. “As we head into cannabis 2.0 and the Canadian cannabis market continues to develop in a highly regulated environment, we expect that distribution will be one of the key tenets of success for brands,” said Narbé Alexandrian, President and CEO of Canopy Rivers.

“Our strategic alliance with Kindred presents a valuable opportunity for our portfolio companies to access the expertise and distribution channels necessary to enable their branded products to thrive. We’re excited to work with Kindred.” RIV stock is trading at $1.76 at the time of writing.

$OGI CBD Company Receives Joint Warning Letter from FTC and FDA

October 25, 2019

This Tuesday, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) posted a joint warning letter to CBD company Rooted Apothecary LLC. The letter cautioned the Naples, Florida-based company against illegally selling CBD-infused products, and making unsubstantiated claims that their products could treat teething pain and earaches in infants, ADHD, Parkinson’s, Alzheimer’s and a host of other diseases.

CBD has been a subject of controversy for the past few years. Tons of people swear that the compound gave them relief from a variety of medical conditions, but there is very little scientific research and evidence to prove this. Furthermore, cannabidiol is derived from the cannabis plant, most famous for the psychotropic high users experience after using it. Last year’s Farm Bill allowed the farming of cannabis, but only if there’s less than 0.3% THC, the component that causes cannabis’ high.

The industry still has little regulation, and some sellers have taken to making unsupported claims to sell more of their products. “Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance,” said Acting FDA Commissioner Ned Sharpless, M.D., “We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat, or cure a number of diseases or conditions.”

He says that it is especially concerning when companies are peddling unproven CBD products for use in vulnerable populations like women and children. “We’ve sent out numerous warning letters that focus on matters of significant public health concerning CBD companies, and these actions should send a message to the broader market about complying with FDA requirements. As we examine potential regulatory pathways for the lawful marketing of cannabis products, protecting and promoting public health through sound, science-based decision making remains our top priority.” Sharpless adds that the FDA appreciates the FTC’s support in its bid to protect consumers from “fraudulent” CBD products.

Rooted Apothecary LLC had used product pages, social media websites, and its online store to make unfounded claims about its CBD products. Some of its products were marketed as dietary supplements despite agency regulation forbidding that. Under the Federal Trade Commission Act, it is illegal to advertise that a product can prevent, treat, or cure human diseases unless the advertiser possesses competent and reliable scientific evidence. To make or exaggerate such claims without sufficient scientific evidence to back the claims would violate the FTC Act.

The FTC and FDA have requested a response from Rooted Apothecary LLC within 15 working days stating how the company will correct the violations. Failure to correct the violations may result in legal action, including seizure and injunctions. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or administrative cease and desist order, and an order may require that a company pay back money to consumers.

Analysts believe that more established CBD companies like IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) and Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) have compliance teams that keep them safe from running afoul of federal regulators. Newer companies can do well to learn from those that came before them if their businesses are to survive.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$TGODF Gives ‘Power to Flower’ in Certified Organic Cultivation Process

October 24, 2019

• TGOD is the only licensed producer to grow certified organic cannabis at scale
• The Green Organic Dutchman’s processes are certified by two of the largest organic certification organizations in the world
• The company’s certified-organic process benefits consumers, the community and the environment

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a global leader in cultivating premium, certified organic cannabis, prides itself on its commitment to producing premium organic cannabis. The company is the only Licensed Producer to grow certified organic cannabis at scale. Maintaining that commitment isn’t easy, but TGOD’s higher standard of organic growing has attracted a strong base of customers who value being able to trust that their products are cultivated in accordance with Canadian organic standards and are not irradiated.

TGOD’s decision to go organic is rooted in the company’s desire to provide its consumers with the highest-quality, healthiest options on the market. The Green Organic Dutchman understands that, for many, cannabis is a life-changing medicine. Patients and consumers alike have no desire to ingest irradiated products.

In addition, research indicates that more than 55 percent of Canadian consumers purchase organic products on a weekly basis, and over 80 percent of those maintained – or increased – their organic purchases in the last year. With that kind of consumer base, along with organic trends growing around the world and its dedication to providing only the best, TGOD’s decision to go organic was a no-brainer.

Growing certified-organic cannabis doesn’t just benefit consumers. The process is also better for the community, the soil and the environment. TGOD’s cultivation process includes creating a living soil designed to build a population of beneficial organisms that provide an enhanced diversity of biology in the soil. That means that when TGOD “hands over the power to the flower,” the plant teams up with the right fungi and healthy bacteria to grow the highest-quality cannabis available.

In an era where the term “organic” is often thrown about casually, clients appreciate knowing that TGOD’s organic claims are officially recognized. TGOD’s processes are certified by both ECOCERT and Pro-Cert, two of the largest organic certification organizations in the world. ECOCERT standards are based on natural and organic principles, including the use of ingredients derived from renewable resources and environmentally friendly process. Pro-Cert’s certification is ISO 17065 compliant and accredited.

While TGOD is committed to being a global leader in certified organic cannabis, the company’s goal is also to create a positive economic impact locally. The company’s community farm produces fresh organic food that it contributes through food donation programs. Finally, because growing organically focuses on the natural growth of the plant, it is a cleaner process. Through its regenerative farming practices, TGOD also reduces its carbon footprint throughout the entire product life cycle.

The Green Organic Dutchman is a publicly traded, premium-cannabis producer in Canada, engaged in growing organic cannabis using craft farming techniques. The company operates in medical cannabis markets in Canada, Europe, the Caribbean, and Latin America, and also supplies to the Canadian adult-use market. TGOD also operates in the CBD-oil markets of Canada and distributes premium-hemp CBD oil in the European Union through its wholly owned subsidiary HemPoland.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://cnw.fm/TGODF

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

$SRAX Presents at Premier Microcap Investor Conference

October 24, 2019

$OGI Florida Finalizes Draft Hemp Rules

October 24, 2019

By the end of 2019, hemp farmers in Florida might be able to submit their hemp applications. On Monday, state officials held the first of the multiple public hearings in Tampa to discuss the Final Draft Rules for the state’s hemp program.

This clarifies that the Department of Agriculture and Consumer Services in Florida is still on track for adoption and review of its rules by the U.S. Department of Agriculture, said Franco Ripple, the agency spokesperson. He further added that the Agricultural Commissioner, Nikki Fred’s main priority was to get the final draft out and hemp seeds in Florida at the earliest time.

Earlier this year, the Florida legislature passed legislation authorizing a hemp program while Governor Ron DeSantis signed the bill into law.

The 2018 Farm Bill legalized the growth of hemp in the U.S. and this allowed states to establish programs for growing hemp, a plant that was previously banned.

In the draft rules, there is a provision for licenses to last for a period of 12 months only and that they should be non-transferable. This will lead to the shutdown of the market for selling licenses. The rule has frustrated some state officials because it will be impossible to transfer licenses once a company changes ownership.

As noted in the draft rules, there is a significant concern as hemp is classified as an invasive species that has the potential of spreading to other farms once planted. This is the reason why security measures must be in place before planting hemp.

According to the draft rules, farmers are required to submit samples of their crop for THC concentration testing before harvesting. THC is a chemical compound in marijuana that gives users the high effect when consumed, and it must be below 0.3% in hemp. The state requires several tests to be conducted to get conclusive results. If the level of concentration is above 0.3%, the rules stipulate that the entire hemp crop should be destroyed.

The draft rules further stipulate that the farmers have to issue a notification to the state before harvesting their crop and to ensure that the product is securely stored once cut. The rules also provide for the safe transportation of hemp products.

The draft rules also set specific standards on the quality of hemp seeds since farmers had previously voiced their concerns on the quality of the available hemp seeds considering the crop is relatively new. The rules state that sellers cannot sell hemp seed with a germination rate of less than 60%.

Earlier this year, Florida Cannabis Director, Holly Bell, forecast that cultivation permits application would be about 8,000 and that about 3,000 farms would start growing hemp at the beginning of 2020.

Experts believe industry players like Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) and Marijuana Company of America Inc. (OTCQB: MCOA) will be watching to see if the predictions come to pass once hemp cultivation gets underway in Florida next year.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

$YGYI Two Studies Show Marijuana is Helping Patients Avoid Opioids

October 24, 2019

Two studies show that patients suffering from chronic pain are using marijuana instead of addictive pharmaceuticals to help them manage the pain.

The studies are an addition to the growing body of research on the importance of marijuana in the growing opioid crisis in the United States.

The first study, carried out by researchers from Florida International University, investigated if managing pain was the only reason people substituted opioids with marijuana. The study was published in the International Journal of Drug Policy. The researchers used data from the National Survey on Drug Use and Health when evaluating the likelihood of opioid consumption by people in states where medical marijuana is legal and where medical marijuana was not available.

The researchers used the following to evaluate the data, did the respondents use or abuse any pain relief medication in the past year, the states they resided in, and if medical cannabis was legal. They analyzed the surveyed data for the year 2015 through to 2017, which included 120,764 respondents.

The study authors concluded that an analysis of the data resulted in a multivariate logistics regression equation, which showed that a reduction in opioid usage is associated with the medical cannabis laws.

The study states that marijuana helped patients minimize their dependence on opioids significantly because in relieving pain, marijuana and opiates are on the same level; however, most patients prefer to use weed over opioids. The patient’s perception of the treatment and tolerance of the side effect is the basis of a successful treatment plan.

The second study was carried out by researchers from the San Francisco Veterans Affairs Medical Center, who asked direct questions to people on whether or not patients use medical marijuana instead of the prescribed painkillers. The study, which was published in PloS, surveyed 16,280 adults where the researchers asked participants to share information on their opioid and cannabis usage. They also asked them to note if there were any changes in the amount of opioids they used after using marijuana and why the patients substituted cannabis for opioid prescriptions.

Those who responded to the survey were more than half the number of participants, whereby 5% (486) said to have used marijuana and opioid in the past year, 43% used opioid daily, and 23% reported to have used marijuana in the past one month. The study also found that 41% of the respondents stopped or reduced their opioid consumption because of marijuana, 46% did not alter their opioid usage, and 8% increased their opioid intake.

The researchers also found that most Americans substituted marijuana for opioids, with 36% crediting it to better at pain management, 32% experienced fewer side effects, and 26% associated it to fewer withdrawal symptoms. Thirteen percent said the medicine was cheap, and the remaining thirteen percent said they used it due to social acceptance.

The two studies show the importance of mitigating opioid use and misuse when caring for patients. And, the Department of Health and Human Services (HHS) Pain Management Inter-Agency echoed the same sentiments earlier this year.

Analysts believe these findings are in line with what the cannabis industry, including actors like Youngevity International Inc. (NASDAQ: YGYI) and Therma Bright Inc. (TSX.V: THRM) (OTC: THBRF), has always known as the benefit of medical marijuana in taming the opioid crisis.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com